{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["BCR::ABL1", "CML", "Leea indica", "gallic acid", "mitochondrial respiration"]], "OtherAbstract": [], "SpaceFlightMission": [], "InvestigatorList": [], "CitationSubset": ["IM"], "OtherID": [], "GeneralNote": [], "PMID": "39063200", "DateCompleted": {"Year": "2024", "Month": "07", "Day": "28"}, "DateRevised": {"Year": "2024", "Month": "07", "Day": "29"}, "Article": {"Language": ["eng"], "ELocationID": ["7958", "10.3390/ijms25147958"], "ArticleDate": [{"Year": "2024", "Month": "07", "Day": "21"}], "Journal": {"ISSN": "1422-0067", "JournalIssue": {"Volume": "25", "Issue": "14", "PubDate": {"Year": "2024", "Month": "Jul", "Day": "21"}}, "Title": "International journal of molecular sciences", "ISOAbbreviation": "Int J Mol Sci"}, "ArticleTitle": "Gallic Acid Enhances the Efficacy of BCR::ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia through Inhibition of Mitochondrial Respiration and Modulation of Oncogenic Signaling Pathways.", "Abstract": {"AbstractText": ["While BCR::ABL1 tyrosine kinase inhibitors have transformed the treatment paradigm for chronic myeloid leukemia (CML), disease progression and treatment resistance due to BCR::ABL1-dependent and BCR::ABL1-independent mechanisms remain a therapeutic challenge. Natural compounds derived from plants have significantly contributed to cancer pharmacotherapy. This study investigated the efficacy of an active component of <i>Leea indica</i>, a local medicinal plant, in CML. Using high-performance liquid chromatography-electrospray ionization-mass spectrometry, a chemical constituent from <i>L. indica</i> extract was isolated and identified as gallic acid. Commercially obtained gallic acid was used as a chemical standard. Gallic acid from <i>L. indica</i> inhibited proliferation and induced apoptosis in CML cell lines, as did the chemical standard. Furthermore, gallic acid induced apoptosis and decreased the colony formation of primary CML CD34<sup>+</sup> cells. The combination of isolated gallic acid or its chemical standard with BCR::ABL1 tyrosine kinase inhibitors resulted in a significantly greater inhibition of colony formation and cell growth compared to a single drug alone. Mechanistically, CML cells treated with gallic acid exhibited the disruption of multiple oncogenic pathways including ERK/MAPK, FLT3 and JAK/STAT, as well as impaired mitochondrial respiration. Rescue studies showed that gallic acid is significantly less effective in inducing apoptosis in mitochondrial respiration-deficient \u03c1<sup>0</sup> cells compared to wildtype cells, suggesting that the action of gallic acid is largely through the inhibition of mitochondrial respiration. Our findings highlight the therapeutic potential of <i>L. indica</i> in CML and suggest that gallic acid may be a promising lead chemical constituent for further development for CML treatment."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Haematology, Singapore General Hospital, National Cancer Centre Singapore, Singapore 169608, Singapore."}], "LastName": "Xiang", "ForeName": "Wei", "Initials": "W"}, {"Identifier": ["0000-0001-6717-7837"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Haematology, Singapore General Hospital, National Cancer Centre Singapore, Singapore 169608, Singapore."}], "LastName": "Sng", "ForeName": "Colin", "Initials": "C"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Haematology, Singapore General Hospital, National Cancer Centre Singapore, Singapore 169608, Singapore."}], "LastName": "Lam", "ForeName": "Yi-Hui", "Initials": "YH"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Haematology, Singapore General Hospital, National Cancer Centre Singapore, Singapore 169608, Singapore."}], "LastName": "Kok", "ForeName": "Ze-Hui", "Initials": "ZH"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Haematology, Singapore General Hospital, National Cancer Centre Singapore, Singapore 169608, Singapore."}], "LastName": "Linn", "ForeName": "Yeh-Ching", "Initials": "YC"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacy and Pharmaceutical Sciences, Faculty of Science, National University of Singapore, Singapore 117543, Singapore."}], "LastName": "Neo", "ForeName": "Soek-Ying", "Initials": "SY"}, {"Identifier": ["0000-0001-7543-0943"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacy and Pharmaceutical Sciences, Faculty of Science, National University of Singapore, Singapore 117543, Singapore."}], "LastName": "Siew", "ForeName": "Yin-Yin", "Initials": "YY"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacy and Pharmaceutical Sciences, Faculty of Science, National University of Singapore, Singapore 117543, Singapore."}], "LastName": "Singh", "ForeName": "Deepika", "Initials": "D"}, {"Identifier": ["0000-0003-1461-9245"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacy and Pharmaceutical Sciences, Faculty of Science, National University of Singapore, Singapore 117543, Singapore."}], "LastName": "Koh", "ForeName": "Hwee-Ling", "Initials": "HL"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Haematology, Singapore General Hospital, National Cancer Centre Singapore, Singapore 169608, Singapore."}, {"Identifier": [], "Affiliation": "Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore 169857, Singapore."}], "LastName": "Chuah", "ForeName": "Charles", "Initials": "C"}], "GrantList": [{"GrantID": "R-148-000-172-592", "Agency": "National University of Singapore-Leeward Pacific Pte Ltd research collaboration grant", "Country": ""}, {"GrantID": "SRG-OPN-06-2023", "Agency": "SGH Research Grant", "Country": ""}, {"GrantID": "AM/TP020/2018", "Agency": "Academia Medical Research Grant", "Country": ""}, {"GrantID": "NMRC/CG/C012A/2017", "Agency": "NMRC Centre Grant Programme -Targeted Therapy for Blood Cancer", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Int J Mol Sci", "NlmUniqueID": "101092791", "ISSNLinking": "1422-0067"}, "ChemicalList": [{"RegistryNumber": "632XD903SP", "NameOfSubstance": "Gallic Acid"}, {"RegistryNumber": "EC 2.7.10.2", "NameOfSubstance": "Fusion Proteins, bcr-abl"}, {"RegistryNumber": "0", "NameOfSubstance": "Protein Kinase Inhibitors"}, {"RegistryNumber": "0", "NameOfSubstance": "Tyrosine Kinase Inhibitors"}], "MeshHeadingList": [{"QualifierName": ["pharmacology"], "DescriptorName": "Gallic Acid"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["drug therapy", "metabolism", "pathology"], "DescriptorName": "Leukemia, Myelogenous, Chronic, BCR-ABL Positive"}, {"QualifierName": ["antagonists & inhibitors", "metabolism"], "DescriptorName": "Fusion Proteins, bcr-abl"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Protein Kinase Inhibitors"}, {"QualifierName": ["drug effects", "metabolism"], "DescriptorName": "Mitochondria"}, {"QualifierName": ["drug effects"], "DescriptorName": "Signal Transduction"}, {"QualifierName": ["drug effects"], "DescriptorName": "Apoptosis"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cell Proliferation"}, {"QualifierName": [], "DescriptorName": "Cell Line, Tumor"}, {"QualifierName": [], "DescriptorName": "Tyrosine Kinase Inhibitors"}], "CoiStatement": "C.C. has received honoraria from Pfizer, Bristol-Myers Squibb, Novartis Oncology, Korea Otsuka Pharmaceutical and Chiltern International. All other authors declare no competing financial interests."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat. Rev. Cancer. 2005;5:172\u2013183. doi: 10.1038/nrc1567.", "ArticleIdList": ["10.1038/nrc1567", "15719031"]}, {"Citation": "Pan Y.L., Zeng S.X., Hao R.R., Liang M.H., Shen Z.R., Huang W.H. The progress of small-molecules and degraders against BCR-ABL for the treatment of CML. Eur. J. Med. Chem. 2022;238:114442. doi: 10.1016/j.ejmech.2022.114442.", "ArticleIdList": ["10.1016/j.ejmech.2022.114442", "35551036"]}, {"Citation": "Hehlmann R. How I treat CML blast crisis. Blood. 2012;120:737\u2013747. doi: 10.1182/blood-2012-03-380147.", "ArticleIdList": ["10.1182/blood-2012-03-380147", "22653972"]}, {"Citation": "Garcia-Oliveira P., Otero P., Pereira A.G., Chamorro F., Carpena M., Echave J., Fraga-Corral M., Simal-Gandara J., Prieto M.A. Status and Challenges of Plant-Anticancer Compounds in Cancer Treatment. Pharmaceuticals. 2021;14:157. doi: 10.3390/ph14020157.", "ArticleIdList": ["10.3390/ph14020157", "PMC7918405", "33673021"]}, {"Citation": "Newman D.J., Cragg G.M. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J. Nat. Prod. 2020;83:770\u2013803. doi: 10.1021/acs.jnatprod.9b01285.", "ArticleIdList": ["10.1021/acs.jnatprod.9b01285", "32162523"]}, {"Citation": "Mukhtar E., Adhami V.M., Mukhtar H. Targeting microtubules by natural agents for cancer therapy. Mol. Cancer Ther. 2014;13:275\u2013284. doi: 10.1158/1535-7163.MCT-13-0791.", "ArticleIdList": ["10.1158/1535-7163.MCT-13-0791", "PMC3946048", "24435445"]}, {"Citation": "Gordaliza M., Castro M.A., del Corral J.M., Feliciano A.S. Antitumor properties of podophyllotoxin and related compounds. Curr. Pharm. Des. 2000;6:1811\u20131839. doi: 10.2174/1381612003398582.", "ArticleIdList": ["10.2174/1381612003398582", "11102564"]}, {"Citation": "Singh D., Siew Y.Y., Chong T.I., Yew H.C., Ho S.S., Lim C.S.E., Tan W.X., Neo S.Y., Koh H.L. Identification of Phytoconstituents in Leea indica (Burm. F.) Merr. Leaves by High Performance Liquid Chromatography Micro Time-of-Flight Mass Spectrometry. Molecules. 2019;24:714. doi: 10.3390/molecules24040714.", "ArticleIdList": ["10.3390/molecules24040714", "PMC6412998", "30781458"]}, {"Citation": "Singh S., Siew Y.Y., Yew H.C., Neo S.Y., Koh H.L. Botany, phytochemistry and pharmacological activities of Leea species. In: Patra K.J.K., Rudramurthy G.R., editors. Medicinal Plants: Chemistry, Pharmacology, and Therapeutic Applications. CRC Press; Boca Raton, FL, USA: 2019. pp. 11\u201341."}, {"Citation": "Hossain F., Mostofa M.G., Alam A.K. Traditional uses and pharmacological activities of the genus leea and its phytochemicals: A review. Heliyon. 2021;7:e06222. doi: 10.1016/j.heliyon.2021.e06222.", "ArticleIdList": ["10.1016/j.heliyon.2021.e06222", "PMC7892933", "33659746"]}, {"Citation": "Siew Y.Y., Yew H.C., Neo S.Y., Seow S.V., Lew S.M., Lim S.W., Lim C.S.E., Ng Y.C., Seetoh W.G., Ali A., et al. Evaluation of anti-proliferative activity of medicinal plants used in Asian Traditional Medicine to treat cancer. J. Ethnopharmacol. 2019;235:75\u201387. doi: 10.1016/j.jep.2018.12.040.", "ArticleIdList": ["10.1016/j.jep.2018.12.040", "30599223"]}, {"Citation": "Yau Hsiung W., Abdul Kadir H. Leea indica Ethyl Acetate Fraction Induces Growth-Inhibitory Effect in Various Cancer Cell Lines and Apoptosis in Ca Ski Human Cervical Epidermoid Carcinoma Cells. Evid.-Based Complement. Altern. Med. eCAM. 2011;2011:293060. doi: 10.1155/2011/293060.", "ArticleIdList": ["10.1155/2011/293060", "PMC3057472", "21423690"]}, {"Citation": "Ghagane S.C., Puranik S.I., Kumbar V.M., Nerli R.B., Jalalpure S.S., Hiremath M.B., Neelagund S., Aladakatti R. In vitro antioxidant and anticancer activity of Leea indica leaf extracts on human prostate cancer cell lines. Integr. Med. Res. 2017;6:79\u201387. doi: 10.1016/j.imr.2017.01.004.", "ArticleIdList": ["10.1016/j.imr.2017.01.004", "PMC5395687", "28462147"]}, {"Citation": "Neo S.Y., Siew Y.Y., Yew H.C., He Y., Poh K.L., Tsai Y.C., Ng S.L., Tan W.X., Chong T.I., Lim C.S.E., et al. Effects of Leea indica leaf extracts and its phytoconstituents on natural killer cell-mediated cytotoxicity in human ovarian cancer. BMC Complement. Med. Ther. 2023;23:79. doi: 10.1186/s12906-023-03904-1.", "ArticleIdList": ["10.1186/s12906-023-03904-1", "PMC10007844", "36899361"]}, {"Citation": "Jang Y.G., Ko E.B., Choi K.C. Gallic acid, a phenolic acid, hinders the progression of prostate cancer by inhibition of histone deacetylase 1 and 2 expression. J. Nutr. Biochem. 2020;84:108444. doi: 10.1016/j.jnutbio.2020.108444.", "ArticleIdList": ["10.1016/j.jnutbio.2020.108444", "32615369"]}, {"Citation": "Aborehab N.M., Elnagar M.R., Waly N.E. Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF-7 human breast cancer cell line. J. Biochem. Mol. Toxicol. 2021;35:e22638. doi: 10.1002/jbt.22638.", "ArticleIdList": ["10.1002/jbt.22638", "33002289"]}, {"Citation": "Zhang T., Ma L., Wu P., Li W., Li T., Gu R., Dan X., Li Z., Fan X., Xiao Z. Gallic acid has anticancer activity and enhances the anticancer effects of cisplatin in nonsmall cell lung cancer A549 cells via the JAK/STAT3 signaling pathway. Oncol. Rep. 2019;41:1779\u20131788.", "ArticleIdList": ["30747218"]}, {"Citation": "Gu R., Zhang M., Meng H., Xu D., Xie Y. Gallic acid targets acute myeloid leukemia via Akt/mTOR-dependent mitochondrial respiration inhibition. Biomed. Pharmacother.=Biomed. Pharmacother. 2018;105:491\u2013497. doi: 10.1016/j.biopha.2018.05.158.", "ArticleIdList": ["10.1016/j.biopha.2018.05.158", "29883944"]}, {"Citation": "Lin X., Wang G., Liu P., Han L., Wang T., Chen K., Gao Y. Gallic acid suppresses colon cancer proliferation by inhibiting SRC and EGFR phosphorylation. Exp. Ther. Med. 2021;21:638. doi: 10.3892/etm.2021.10070.", "ArticleIdList": ["10.3892/etm.2021.10070", "PMC8097205", "33968169"]}, {"Citation": "Chandramohan Reddy T., Bharat Reddy D., Aparna A., Arunasree K.M., Gupta G., Achari C., Reddy G.V., Lakshmipathi V., Subramanyam A., Reddanna P. Anti-leukemic effects of gallic acid on human leukemia K562 cells: Downregulation of COX-2, inhibition of BCR/ABL kinase and NF-kappaB inactivation. Toxicol Vitr. 2012;26:396\u2013405. doi: 10.1016/j.tiv.2011.12.018.", "ArticleIdList": ["10.1016/j.tiv.2011.12.018", "22245431"]}, {"Citation": "Chou T.C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440\u2013446. doi: 10.1158/0008-5472.CAN-09-1947.", "ArticleIdList": ["10.1158/0008-5472.CAN-09-1947", "20068163"]}, {"Citation": "Rex M.R., Williams R., Birsoy K., Ta Llman M.S., Stahl M. Targeting mitochondrial metabolism in acute myeloid leukemia. Leuk Lymphoma. 2022;63:530\u2013537. doi: 10.1080/10428194.2021.1992759.", "ArticleIdList": ["10.1080/10428194.2021.1992759", "34704521"]}, {"Citation": "Xiang W., Cheong J.K., Ang S.H., Teo B., Xu P., Asari K., Sun W.T., Than H., Bunte R.M., Virshup D.M., et al. Pyrvinium selectively targets blast phase-chronic myeloid leukemia through inhibition of mitochondrial respiration. Oncotarget. 2015;6:33769\u201333780. doi: 10.18632/oncotarget.5615.", "ArticleIdList": ["10.18632/oncotarget.5615", "PMC4741801", "26378050"]}, {"Citation": "Dehelean C.A., Marcovici I., Soica C., Mioc M., Coricovac D., Iurciuc S., Cretu O.M., Pinzaru I. Plant-Derived Anticancer Compounds as New Perspectives in Drug Discovery and Alternative Therapy. Molecules. 2021;26:1109. doi: 10.3390/molecules26041109.", "ArticleIdList": ["10.3390/molecules26041109", "PMC7922180", "33669817"]}, {"Citation": "Shanmugam M.K., Lee J.H., Chai E.Z., Kanchi M.M., Kar S., Arfuso F., Dharmarajan A., Kumar A.P., Ramar P.S., Looi C.Y., et al. Cancer prevention and therapy through the modulation of transcription factors by bioactive natural compounds. Semin. Cancer Biol. 2016;40\u201341:35\u201347. doi: 10.1016/j.semcancer.2016.03.005.", "ArticleIdList": ["10.1016/j.semcancer.2016.03.005", "27038646"]}, {"Citation": "Bishayee A., Sethi G. Bioactive natural products in cancer prevention and therapy: Progress and promise. Semin. Cancer Biol. 2016;40\u201341:1\u20133. doi: 10.1016/j.semcancer.2016.08.006.", "ArticleIdList": ["10.1016/j.semcancer.2016.08.006", "27565447"]}, {"Citation": "Saralamp P. Vol. 1 Department of Pharmaceutical Botany, Faculty of Pharmacy, Mahidol University; Bangkok, Thailand: 1996. Medicinal plants in Thailand."}, {"Citation": "Chomel J.C., Bonnet M.L., Sorel N., Sloma I., Bennaceur-Griscelli A., Rea D., Legros L., Marfaing-Koka A., Bourhis J.H., Ame S., et al. Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation. Oncotarget. 2016;7:35293\u201335301. doi: 10.18632/oncotarget.9182.", "ArticleIdList": ["10.18632/oncotarget.9182", "PMC5085229", "27167108"]}, {"Citation": "Wang D., Bao B. Gallic Acid Impedes Non-Small Cell Lung Cancer Progression via Suppression of EGFR-Dependent CARM1-PELP1 Complex. Drug Des. Devel. Ther. 2020;14:1583\u20131592. doi: 10.2147/DDDT.S228123.", "ArticleIdList": ["10.2147/DDDT.S228123", "PMC7186892", "32425504"]}, {"Citation": "Brahmbhatt J., Kumar S.P., Bhadresha K., Patel M., Rawal R. Targeting leukemic stem cell subpopulation in AML using phytochemicals: An in-silico and in-vitro approach. Comput. Biol. Med. 2023;155:106644. doi: 10.1016/j.compbiomed.2023.106644.", "ArticleIdList": ["10.1016/j.compbiomed.2023.106644", "36774886"]}, {"Citation": "Vetrie D., Helgason G.V., Copland M. The leukaemia stem cell: Similarities, differences and clinical prospects in CML and AML. Nat. Rev. Cancer. 2020;20:158\u2013173. doi: 10.1038/s41568-019-0230-9.", "ArticleIdList": ["10.1038/s41568-019-0230-9", "31907378"]}, {"Citation": "Li S. SRC kinase signaling in leukaemia. Int. J. Biochem. Cell Biol. 2007;39:1483\u20131488. doi: 10.1016/j.biocel.2007.01.027.", "ArticleIdList": ["10.1016/j.biocel.2007.01.027", "PMC2063586", "17350876"]}, {"Citation": "Kim J.H., Chu S.C., Gramlich J.L., Pride Y.B., Babendreier E., Chauhan D., Salgia R., Podar K., Griffin J.D., Sattler M. Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood. 2005;105:1717\u20131723. doi: 10.1182/blood-2004-03-0849.", "ArticleIdList": ["10.1182/blood-2004-03-0849", "15486067"]}, {"Citation": "Lagadinou E.D., Sach A., Callahan K., Rossi R.M., Neering S.J., Minhajuddin M., Ashton J.M., Pei S., Grose V., O\u2019Dwyer K.M., et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013;12:329\u2013341. doi: 10.1016/j.stem.2012.12.013.", "ArticleIdList": ["10.1016/j.stem.2012.12.013", "PMC3595363", "23333149"]}, {"Citation": "Jaras M., Ebert B.L. Power cut: Inhibiting mitochondrial translation to target leukemia. Cancer Cell. 2011;20:555\u2013556. doi: 10.1016/j.ccr.2011.10.028.", "ArticleIdList": ["10.1016/j.ccr.2011.10.028", "22094249"]}]}], "History": [{"Year": "2024", "Month": "5", "Day": "29"}, {"Year": "2024", "Month": "7", "Day": "12"}, {"Year": "2024", "Month": "7", "Day": "16"}, {"Year": "2024", "Month": "7", "Day": "28", "Hour": "14", "Minute": "53"}, {"Year": "2024", "Month": "7", "Day": "27", "Hour": "10", "Minute": "47"}, {"Year": "2024", "Month": "7", "Day": "27", "Hour": "1", "Minute": "14"}, {"Year": "2024", "Month": "7", "Day": "21"}], "PublicationStatus": "epublish", "ArticleIdList": ["39063200", "PMC11276718", "10.3390/ijms25147958", "ijms25147958"]}}]}